2027 Pharma L&D Planning: Key Questions, Flat Budgets, and the Trends Reshaping Training Design

Amy Badovick Thursday, November 19, 2026

Most life sciences L&D leaders are building their 2027 plans against the same constraint: a budget that looks much like this year’s (or smaller), set against a launch calendar, a field environment, and a policy landscape that look very different. The plans that hold up through the year will not be the ones with the longest program list. They will be the ones that answer a few hard questions early, put every dollar against a business outcome, and design training around how each function’s work is changing.

This article outlines the questions to settle before a plan is final, practical ways to get more from a flat budget, and the Medical Affairs, Commercial, and Market Access trends that should shape program design in 2027.

Why Is 2027 L&D Planning Different for Life Sciences Teams?

Flat budgets are now the norm. TalentLMS benchmark research found training spend converging toward stable, standardized budgets, and argues that holding steady amid inflation and tighter margins reflects more intentional, measured investment.[1] The cost side is moving the other way. ATD’s 2025 State of the Industry report put average direct learning expenditure at $1,254 per employee, while the average cost per learning hour used rose roughly 34 percent, to $165.[2] A flat line item, in other words, buys less learning than it did a year ago.

For pharma and biotech teams, that pressure is compounded by industry realities: content that must clear medical, legal, and regulatory review, learners who spend most of their time in the field, and launch timelines that rarely move to accommodate training.

Seven Questions to Answer As You Finalize a 2027 L&D Plan

  1. Which business outcomes will this plan be measured against? Launch readiness, time to field certification, quality of scientific exchange, and payer conversation outcomes are stronger anchors than completion rates.

  2. What is on the 2027 launch and lifecycle calendar? New indications, label updates, and loss-of-exclusivity events should drive sequencing, not the fiscal calendar.

  3. Which existing programs are performing, and how do we know? If the evidence is limited to satisfaction scores, renewals will be hard to defend.

  4. Where are the largest capability gaps by role? A new MSL and a seasoned account director need different things, and one curriculum rarely serves both.

  5. What external changes will alter what learners need to know? Policy, HCP behavior, and technology shifts can date a curriculum by midyear.

  6. How much review capacity is available? MLR cycles are a real constraint, and plans that ignore them slip.

  7. What will we stop doing? A flat budget works only if you retire lower-value activity to fund higher-value work.

How Can L&D Leaders Make a Flat Training Budget Work Harder?

Treat the 2027 plan as a portfolio rather than a list. A simple four-way sort clarifies decisions quickly:

  • Protect: programs with clear performance evidence and direct ties to launch or compliance requirements.

  • Optimize: programs with sound content but weak reinforcement, measurement, or delivery formats.

  • Retire: legacy courses with low usage, outdated content, or no link to a current priority.

  • Invest: a small number of new initiatives aimed at the highest-stakes 2027 outcomes.

The Optimize category usually holds the largest untapped return, and it lets leaders show progress without requesting new funding. A modest contingency reserve also gives teams room to respond to label changes or competitive events without reopening the full plan.

How to Get More from Existing Training Programs

The fastest way to raise the return on a training budget is to protect the investment already made. Learning that is not reinforced fades quickly; a widely cited replication of Ebbinghaus’s forgetting curve found steep retention losses within the first day after learning.[3] Practical moves include:

  • Add spaced reinforcement to high-value programs through short scenario-based refreshers, knowledge checks, and coaching prompts timed after the initial event.

  • Modularize long courses so content can be updated, reused across brands, and resubmitted for review in smaller pieces.

  • Refresh rather than rebuild when the core science is stable and only the competitive or access context has changed.

  • Equip front-line managers to coach to the training, since manager reinforcement often separates knowledge from behavior change.

Evaluation matters as much as design. As we explored in why sales training must shift from completion to outcomes, the programs that earn renewed funding are the ones that can show changed field performance.

How Should New Training Programs Be Designed in 2027?

New programs should clear a higher bar. Before approving one, define the business outcome, the behaviors it must change, and how those changes will be measured at 30, 60, and 90 days. Build reinforcement and measurement into the design from the start, and plan review timelines alongside development timelines so launch-critical content is ready when learners need it.

Which Commercial, Medical Affairs, and Market Access Trends Will Shape Training Design?

Each function faces its own set of shifts, and training design should reflect each one on its own terms.

Medical Affairs: AI Raises the Bar for Scientific Exchange

Clinicians now have AI at their fingertips. Veeva reports that nearly 70 percent of HCPs use AI daily to get scientific information on patient care,[4] yet close to 75 percent of KOLs still want to engage directly with an MSL for deeper pipeline insight.[5] Data recall is no longer a differentiator. MSL programs in 2027 should emphasize scientific judgment, handling ambiguity, insight generation, and the depth of dialogue AI may not support. Medical Affairs is also moving from activity-based metrics toward outcomes such as decision influence and clinical impact,[6] which should inform how MSL training is evaluated. Read more in MSL Training That Moves KOLs.

Commercial: The Field Force Evolves from Messenger to Partner

Commercial models continue to evolve. Recent industry analysis describes representatives working within coordinated pods and connecting with direct-to-patient and other emerging channels rather than operating alone.[7] For training, that means fewer product-detail modules and more emphasis on account planning, reading engagement data, hybrid conversation skills, and making every limited HCP interaction count. Our article You’ve Got 90 Seconds with That HCP looks at what field readiness requires when time is short.

Market Access: Policy Changes Raise the Evidence Bar

In the U.S., Medicare-negotiated prices for a second set of 15 drugs take effect in 2027,[8] and negotiation expands to Part B drugs for 2028.[9] In Europe, mandatory Joint Clinical Assessments extend to orphan medicines in January 2028 and to all new medicines in 2030.[10] Market Access teams will need stronger fluency in value evidence, payer economics, and shifting contracting dynamics. Training should prioritize HEOR and real-world evidence communication, payer objection handling, and scenario practice grounded in current policy. See Beyond Clinical Data: Preparing Market Access Teams to Communicate RWE and HEOR.

Build a 2027 L&D Plan That Proves Its Value

A flat budget does not have to mean a flat year. With the right questions answered early, a disciplined portfolio, and programs designed around how each function’s work is changing, L&D leaders can enter 2027 with a plan that is easier to defend and more likely to deliver.

ERS has supported life sciences organizations for more than 30 years, across 150+ product launches and 50+ therapeutic areas. As a strategic partner to L&D teams, we help leaders assess current programs, prioritize investments, and design training built for measurable performance.

Working on your 2027 strategy? Schedule a 2027 L&D planning session with an ERS team member or contact us at lifesciences@educationalresource.com or 732.842.0202.


Frequently Asked Questions About 2027 L&D Planning

What should a 2027 pharma L&D plan include?

A strong plan defines the business outcomes it will be measured against, sequences programs to the launch and lifecycle calendar, reviews existing program performance, identifies capability gaps by role, accounts for MLR review capacity, and builds reinforcement and measurement into every major program.

How can L&D teams do more with a flat training budget?

Sort the portfolio into programs to protect, optimize, retire, and invest in. Optimizing existing programs with reinforcement, modular updates, and manager coaching typically delivers the highest return while requiring minimal new funding.

How is AI changing MSL training?

Because most HCPs now use AI to access scientific information, MSLs add value through scientific judgment, insight generation, and deeper dialogue. Training should build those skills rather than focus mainly on data recall.

How will Medicare drug price negotiation affect Market Access training?

With negotiated prices for 15 more drugs taking effect in 2027 and Part B drugs added for 2028, Market Access teams need stronger skills in HEOR, real-world evidence, payer economics, and objection handling grounded in current policy.

How should pharma measure training effectiveness?

Look beyond completions and satisfaction scores to behavior change and business results, such as time to certification, field performance, and the quality of scientific or payer conversations, measured at set intervals after training.

 

ERS

The Galleria
2 Bridge Avenue, #632
Red Bank, New Jersey 07701
Email: lifesciences@educationalresource.com

© 2026 Educational Resource Systems, All Rights Reserved

By using this website you accept our privacy policy. Choose the browser data you consent to allow:

Only Required
Accept and Close